We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Randox Presents Future of Diagnostic Technology

By LabMedica International staff writers
Posted on 21 May 2023
Image: The Vivalytic all-in-one solution for molecular diagnostics (Photo courtesy of Randox)
Image: The Vivalytic all-in-one solution for molecular diagnostics (Photo courtesy of Randox)

Randox Laboratories (Crumlin, UK) is showcasing its extensive range of innovative products that are revolutionizing healthcare at the 2023 EuroMedLab Congress.

At EuroMedLab Rome 2023, Randox is introducing the new Acusera third-party controls designed for comprehensive test menu consolidation in laboratory internal quality control. These third-party controls are "true," meaning they are not biased towards or optimized for any specific reagent, method, or instrument, and hence offer an objective assessment of performance. Notably, several Acusera controls are produced using 100% human materials, mimicking a patient sample's behavior and thus providing an accurate reflection of the test system's performance.

Also on display at the industry event is Randox's Vivalytic, an all in one molecular diagnostic solution. This compact benchtop platform consolidates the complete molecular workflow, including extraction, PCR amplification, and detection. The unique multiplex Biochip Technology from Randox powers the Vivalytic, yielding multiple results from a single patient sample. The biochip detection system based on a chemiluminescent signal, which is the emission of light without heat from a chemical reaction. Each biochip is pre-engineered with spatially distinct testing regions (DTRs), each representing an individual test. Each DTR can be occupied with oligonucleotides specific to a pathogen or target of interest, allowing the high-plex capabilities of the Biochip Technology to eliminate the need for running multiple, time-consuming, and sample-intensive assays.

Randox is holding live demonstrations of ACUSERA 24•7 Interlaboratory Data Management which provides instant access to an unrivalled range of features including QC multi-rules, interactive charts, live peer group data, automatic calculation of Measurement Uncertainty & Sigma Metrics & a unique dashboard interface, all designed to speed up the review process and provide at-a-glance performance assessment. Randox is also demonstrating RIQAS (Randox International Quality Assessment Scheme which is used by more than 55,000 laboratory participants in 134 countries and accredited to ISO 17043. As a result, Randox has RIQAS users on every continent who are registered for one or more of its 36 flexible EQA programs, utilizing the available data to ensure the quality and reliability of their results.

ACUSERA 24•7 Interlaboratory Data Management, a feature-rich platform offering QC multi-rules, interactive charts, live peer group data, automatic calculation of Measurement Uncertainty & Sigma Metrics & a unique dashboard interface. All these features are designed to expedite the review process and provide at-a-glance performance assessment. Further, Randox is also demonstrating its RIQAS (Randox International Quality Assessment Scheme), an ISO 17043-accredited scheme employed by over 55,000 lab participants across 134 countries. Thanks to its global footprint, Randox has RIQAS users in every continent who are registered for one or more of its 36 flexible EQA programs, thereby leveraging available data to assure the quality and dependability of their results.

Related Links:
Randox Laboratories 

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Human Estradiol Assay
Human Estradiol CLIA Kit

Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more